Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Locally Advanced Non-resectable Breast Cancer”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Testing effectiveness (Phase 2)Looking for participantsNCT05269381
What this trial is testing

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+98 more
Mayo Clinic 138
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Study completedNCT05181462
What this trial is testing

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Triple Negative Breast Cancer
Cantargia AB 117
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07376629
What this trial is testing

HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Who this might be right for
TNBC
Huabo Biopharm Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT03106415
What this trial is testing

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaMetastatic Triple-Negative Breast CarcinomaStage III Breast Cancer AJCC v7+4 more
Mayo Clinic 23
Testing effectiveness (Phase 2)Ended earlyNCT04958785
What this trial is testing

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Gilead Sciences 92
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Testing effectiveness (Phase 2)Study completedNCT03310957
What this trial is testing

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Seagen Inc. 185
Early research (Phase 1)Looking for participantsNCT05422794
What this trial is testing

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244874
What this trial is testing

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerPD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 41
Testing effectiveness (Phase 2)UnknownNCT04129996
What this trial is testing

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623642
What this trial is testing

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Who this might be right for
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic Neoplasms+8 more
GV20 Therapeutics 227
Large-scale testing (Phase 3)Study completedNCT04148911
What this trial is testing

Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 184
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07762703
What this trial is testing

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
BreakBio Corp 10
Testing effectiveness (Phase 2)UnknownNCT05670925
What this trial is testing

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Study completedNCT04464174
What this trial is testing

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
MedSIR 54
Next Page
57